Viridian Therapeutics, Inc. (VRDN) reported that Chief Legal Officer Jennifer Tousignant exercised stock options and sold shares on August 19, 2026. She exercised options to acquire 10,000 shares of common stock at $14.41 per share, then sold a total of 14,212 shares of common stock at $24.50 per share in open-market or private transactions, including 718 shares previously acquired under the company’s Employee Stock Purchase Plan. Following the option exercise, 114,072 option shares remain outstanding under the reported grant, which was issued on March 3, 2025 and vests in 48 equal monthly installments through March 3, 2029, with an expiration date of March 3, 2035.
Viridian Therapeutics, Inc. (VRDN) is reported to have 5,687,507 shares of its common stock beneficially owned, representing 5.0% of the class, by a group led by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen as of August 19, 2026.
The shares are held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management. The reporting persons have shared voting and dispositive power over these 5,687,507 shares and no sole voting or dispositive power. They state that the filing should not be construed as an admission of beneficial ownership under Section 13 of the Exchange Act.
Viridian Therapeutics, Inc. (VRDN) is the issuer of common stock that an officer, Jennifer Tousignant, has notified an intention to sell under Rule 144. The notice covers 14,212 shares of common stock, with an aggregate market value of $348,194.00, and lists 113,292,269 shares outstanding. The planned sales, through Fidelity Brokerage Services LLC on NASDAQ around August 19, 2026, are sourced from restricted stock vesting, an ESPP purchase, and a stock option exercise.
Viridian Therapeutics, Inc. (VRDN) reported that its Chief Medical Officer, Radhika Tripuraneni, exercised a stock option for 40,000 shares of common stock on 2026-08-14 at an exercise price of $13.21 per share. The exercised option, which was fully vested, now shows 0 derivative shares remaining, and her directly held common stock position increased to 40,000 shares following the transaction.
Viridian Therapeutics, Inc. received an updated Schedule 13G/A reporting significant ownership by Paradigm BioCapital entities and Senai Asefaw, M.D. Paradigm BioCapital Advisors LP, its general partner, and Senai Asefaw each report beneficial ownership of 6,723,788 shares of Viridian common stock, representing 6.1% of the outstanding class as of the June 30, 2026 event date. Paradigm BioCapital International Fund Ltd. directly holds 5,896,154 shares, or 5.3% of the class. The ownership percentages are based on 110,427,682 shares outstanding as of May 11, 2026, following a Viridian common stock offering. The reporting parties state they have sole voting and dispositive power over their reported shares and disclaim beneficial ownership beyond shares directly held by each.
Kynam Capital Management, LP, its general partner Kynam Capital Management GP, LLC, and Yue Tang report their ownership in Viridian Therapeutics, Inc. common stock on an amended Schedule 13G. The group reports shared voting and dispositive power over 6,453,877 shares, representing 5.7% of the common stock. Each reporting person lists no sole voting or dispositive power and an aggregate amount beneficially owned of 0, while detailing the same shared voting and dispositive position. The securities are Viridian common stock, $0.01 par value, CUSIP 92790C104.
T. Rowe Price Associates, Inc. reported beneficial ownership of common stock of Viridian Therapeutics, Inc. as of June 30, 2026. The firm reported holding 5,748,426 shares of Viridian common stock, representing 5.2% of the class. T. Rowe Price Associates reported sole voting power over 5,748,380 shares and sole dispositive power over 5,748,426 shares, with no shared voting or dispositive power. The filing states that T. Rowe Price Associates denies beneficial ownership of the securities referenced.
Viridian Therapeutics, Inc. is reported to have 3,592,740 shares of its common stock beneficially owned by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin in a joint filing. This position represents 3.25% of the company’s common stock, based on 110,427,682 shares outstanding as of May 8, 2026. All 3,592,740 shares are held with shared voting and dispositive power and no sole power, with ownership information stated as of June 30, 2026.
State Street Corporation reported a significant ownership position in Viridian Therapeutics, Inc.6,124,976 shares of Viridian common stock, representing 5.5% of the class.
All voting and dispositive authority over these shares is reported as shared, with 5,894,254 shares subject to shared voting power and 6,124,976 shares subject to shared dispositive power, and no shares under sole power. The position is held through subsidiaries including SSGA Funds Management, Inc. and several State Street Global Advisors entities.
Viridian Therapeutics is transitioning to a commercial-stage biopharma after U.S. approval of veligrotug, trade name Lumvoa, in June 2026 for thyroid eye disease. The company is also advancing elegrobart, a subcutaneous TED antibody, a thyroid stimulating hormone receptor program, and FcRn inhibitors VRDN-006 and VRDN-008.
For the three months ended June 30, 2026, total revenue was modest and primarily from license and collaboration fees, while research and development expense was $71,577 (in thousands) and selling, general and administrative expense was $54,975 (in thousands), leading to continued net losses. For the first half of 2026, the net loss reached $232,020 (in thousands), reflecting heavy investment in development and commercialization.
Liquidity remains strong, with $981.5 million in cash, cash equivalents and marketable securities as of June 30, 2026, which management expects to fund planned operations for at least twelve months. In 2026 the company issued $250.0 million of 1.75% convertible senior notes due 2032 and completed a $143.8 million common stock offering, then repaid its Hercules term loan. Non-dilutive funding includes a revenue participation arrangement with DRI that generated a $75.0 million milestone on veligrotug approval but carries a 27.4% effective interest rate and future U.S. sales-based royalties. Accumulated deficit was $1,570.5 million, underscoring reliance on external capital and eventual product uptake.